SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn’s disease.1 MONTREAL, QC – AbbVie (NYSE: ABBV) announced that SKYRIZI®… Read More
GERMANTOWN, MD – uBriGene Biosciences(uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for its innovative iPSC Reprogramming mRNA-LNP Kit…. Read More
WOOD DALE, IL – PHC Corporation of North America (PHCNA), supplier of the PHCbi brand of preservation and growth products in North America and Latin America, has launched a next-generation… Read More
VANCOUVER, BC – Nimbus Synergies is pleased to announce its investment in EmergConnect, a pioneering digital health platform addressing Canada’s emergency department (ED) crisis. As part of a $1.75M CAD… Read More
QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord1 Biogen’s second rare disease therapy… Read More
